Kendle

Roberto J. Bitton, M.D. has been appointed project leader, Latin America, Kendle. In this role, he will provide medical and therapeutic expertise for Phase I-IV clinical development projects for the company’s biopharmaceutical customers, with an emphasis on oncology therapeutics. Dr. Bitton is a board-certified medical oncologist and has more than 20 years of academic, CRO and pharmaceutical industry experience. He has led clinical teams in every phase of the oncology drug development process.

“Oncology now ranks as the most researched therapeutic area worldwide in terms of drug development,” said Martha Feller, Ph.D., senior vice president, global clinical development, Kendle. “Dr. Bitton’s extensive oncology expertise will further strengthen our therapeutic experience in this significant and growing area of global clinical development.”

Dr. Bitton most recently served as medical manager, South Latin America Sub-Region for Novartis Oncology, where he was responsible for late phase and medical marketing. Prior to that, he served as associate medical director, leading the efforts for various cancer vaccines from R&D through Phase II trials for an independent pharmaceutical company in Argentina, and as a program leader in the clinical oncology department for Pharmacia-Upjohn in Milan, Italy.

“Dr. Bitton’s full-spectrum background in oncology is critically important as the focus in drug development continues to shift beyond simply bringing a new compound to market toward effectively managing the entire life cycle of each drug,” added Dr. Feller.